Business Context and Reporting Period
This Form 8-K Current Report was filed by iBio, Inc. on May 4, 2011, covering events occurring on May 3, 2011. The filing primarily addresses a change in senior management.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial details disclosed relate to executive compensation:
- Base Salary: $165,000 annually for the new Chief Financial Officer.
- Equity Grant: Stock option to purchase 100,000 shares of common stock.
- Vesting Schedule: Three equal annual installments beginning on the first anniversary of service.
- Exercise Price: Set at the last trading price on the date of appointment.
Material Changes
The material change reported is the appointment of Douglas Beck as Chief Financial Officer, effective May 3, 2011. He replaces Frederick Larcombe, who will remain with the company until the filing of the next quarterly report on Form 10-Q to ensure a transition.
Management Commentary and Risks
Management highlighted Mr. Beck's qualifications, noting his status as a CPA and his previous role as CFO of Lev Pharmaceuticals, Inc. (2005–2009). The filing states there are no undisclosed arrangements regarding his selection and no transactions requiring disclosure under Item 404(a) of Regulation S-K. No specific risks, contingencies, or unusual items were disclosed in this report.
Investor Verification Checklist
- Verify the transition timeline for Frederick Larcombe's departure relative to the next 10-Q filing.
- Confirm the exact exercise price of the 100,000 stock options granted to Douglas Beck based on the May 3, 2011 closing price.
- Review the attached press release (Exhibit 99.1) for additional strategic context regarding the leadership change.
- Check subsequent 10-Q filings for the impact of this appointment on the company's financial reporting and internal controls.